m7GHub

m7GHub provides a centralized resource of experimentally validated internal N7-methylguanosine (m7G) sites in messenger RNA (mRNA) and computational tools to predict site occurrence and assess impacts of genetic mutations for studies of mRNA regulation and disease.


Key Features:

  • Internal mRNA m7G Database: Contains over 44,058 experimentally validated internal mRNA m7G sites across mammalian transcriptomes.
  • High-accuracy predictor: Uses sequence-based algorithms to predict the presence of internal m7G sites.
  • Mutation impact assessment web server: Evaluates how genetic mutations may influence internal m7G status.
  • Disease-associated genetic mutations database: Records 1,218 disease-associated genetic mutations that may affect m7G regulation.

Scientific Applications:

  • Study of mRNA regulation: Enables investigation of how internal m7G modifications influence gene expression regulation.
  • RNA stability and translation: Supports analyses of potential effects of internal m7G on RNA stability and translation efficiency.
  • Disease mechanism investigation: Facilitates exploration of links between alterations in m7G methylation and disease-associated mutations.

Methodology:

The resource integrates experimentally validated site data with computational tools; predictive algorithms are based on sequence analysis, and the mutation impact assessment applies bioinformatics approaches to predict how genetic variants might alter m7G status.

Topics

Details

Tool Type:
api, web application
Added:
1/18/2021
Last Updated:
2/19/2021

Operations

Publications

Song B, Tang Y, Chen K, Wei Z, Rong R, Lu Z, Su J, de Magalhães JP, Rigden DJ, Meng J. m7GHub: deciphering the location, regulation and pathogenesis of internal mRNA N7-methylguanosine (m7G) sites in human. Bioinformatics. 2020;36(11):3528-3536. doi:10.1093/bioinformatics/btaa178. PMID:32163126.

PMID: 32163126
Funding: - National Natural Science Foundation of China: 31671373 - XJTLU Key Program Special Fund: KSF-T-01 - XJTLU Key Programme Special Fund: KSF-P-02